Professor David Haslam
NHS England’s Sovaldi fund: opening the floodgates?
July 26, 2014Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CDG, NICE, Professor David Haslam, hep C, sovaldi
Whilst seemingly more and more barriers are being erected to slow down the adoption of new medicines, there is a …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
The evidence bar impacting UK medical cannabis access
November 6, 2026
